{"id":"W2038934354","doi":"10.3747/co.19.1114","title":"Treatment Paradigms for Patients with Metastatic Non-Small-Cell Lung Cancer: First-, Second-, and Third-Line","year":2012,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":132,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Pemetrexed; Erlotinib; Oncology; Internal medicine; Lung cancer; Crizotinib; Carboplatin; Docetaxel; Chemotherapy; Bevacizumab; Gefitinib; Cetuximab; Cancer; Epidermal growth factor receptor; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":true,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001782431,0.0004586494,0.0005767027,0.0005171704,0.001171135,0.001461914,0.00100798,0.001381491,0.005059199],"category_scores_gemma":[0.0023101,0.0001553583,0.001222149,0.000388617,0.0005647805,0.001775038,0.001457094,0.004214459,0.00243846],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003049638,"about_ca_system_score_gemma":0.003316361,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002704544,"about_ca_topic_score_gemma":0.009349979,"domain_scores_codex":[0.9990757,0.0002531271,0.0001113548,0.0001512101,0.0002838284,0.0001248728],"domain_scores_gemma":[0.9989861,0.0001411526,0.000200638,0.00004270501,0.0002690459,0.0003603334],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.002105022,0.001093392,0.01356281,0.002618893,0.0002732066,0.001192092,0.0009112933,0.001564375,0.01004724,0.02035284,0.1374761,0.8088028],"study_design_scores_gemma":[0.001192548,0.002991696,0.024414,0.002491628,0.0003288779,0.006921567,0.001118228,0.001673068,0.004261352,0.0230825,0.9314033,0.0001213271],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"review","genre_scores_codex":[0.1175733,0.2971754,0.03496954,0.4108555,0.006843997,0.002322332,0.002274577,0.0008923466,0.127093],"genre_scores_gemma":[0.5699497,0.1686116,0.0687819,0.1419816,0.007326342,0.003629725,0.00613294,0.0003737437,0.03321238],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.005059199,"threshold_uncertainty_score":0.02212679,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05009744908512064,"score_gpt":0.3993068974870531,"score_spread":0.3492094484019325,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}